| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H32O4 |
| Molecular Weight | 372.4978 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)C[C@H](C)[C@]3([H])[C@@]4([H])CCC(=O)C=C4CC[C@@]23[H]
InChI
InChIKey=IWSXBCZCPVUWHT-VIFKTUCRSA-N
InChI=1S/C23H32O4/c1-13-12-22(4)20(9-10-23(22,14(2)24)27-15(3)25)19-7-5-16-11-17(26)6-8-18(16)21(13)19/h11,13,18-21H,5-10,12H2,1-4H3/t13-,18-,19-,20-,21+,22-,23-/m0/s1
| Molecular Formula | C23H32O4 |
| Molecular Weight | 372.4978 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Norgestomet is a synthetic derivative of progesterone with improved oral activity due to its 17α-acetate side chain. In veterinary medicine norgestomet is used for the synchronisation of oestrus in cattle. It is administered as a subcutaneous ear implant (containing 3 mg norgestomet;
to be removed after 9 to 10 days), in combination with a single intramuscular injection containing 3 mg norgestomet and 5 mg oestradiol valerate. The injection is to be given immediately after application of the implant. Norgestomet is not used in human medicine. It is a steroidal progestin of the 19-norprogesterone group.
Approval Year
PubMed
Patents
Sample Use Guides
Cattle: It is administered as a subcutaneous ear implant (containing 3 mg norgestomet;
to be removed after 9 to 10 days), in combination with a single intramuscular injection containing
3 mg norgestomet and 5 mg oestradiol valerate. The injection is to be given immediately after
application of the implant.
Route of Administration:
Other
Estimated values at which 50% of the specific binding of 16 nM [3H]progesterone was competitively inhibited separately by unlabeled
norgestomet or progesterone, were 2.44 nM and 17.7 nM, respectively.
Half-maximal stimulation of response by norgestomet was approximately 50 uM, although stimulation never exceeded 50% any of the concentrations used, and the relative estrogenic activity of norgestomet was 20
million-fold weaker than the activity of 17b-estradiol. Estrogenic activity was observed only
above 1 uM (about 0.3 ug/ml). Addition of norgestomet (10 uM) to culture media increased (p<.01) estrogenic activity
